Evidence of the dual mechanisms of action of venlafaxine

Archives of General Psychiatry

Volumn 57, Issue 5, 2000, Pages 503-509

  Harvey, Anne T ^a   Rudolph, Richard L ^b   Preskorn, Sheldon H ^a  

^a University of Kansas School of Medicine Wichita Psychiatric Research Institute   (United States)

^b WYETH AYERST RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

MAPROTILINE; NORADRENALIN UPTAKE INHIBITOR; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; TYRAMINE; VENLAFAXINE;

ADULT; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEPRESSION; DOSE RESPONSE; DRUG INDUCED DISEASE; DRUG MECHANISM; HUMAN; HUMAN EXPERIMENT; HYPERTENSION; MALE; NORADRENALIN RELEASE; NORMAL HUMAN; PRESSOR RESPONSE; RANDOMIZED CONTROLLED TRIAL; SEROTONIN UPTAKE; THROMBOCYTE;

EID: 0034057952     PISSN: 0003990X     EISSN: None     Source Type: Journal    
DOI: 10.1001/archpsyc.57.5.503     Document Type: Article

References (27)

1. Effexor [package insert]. Philadelphia, Pa: Wyeth-Ayerst; 1996.
2. Haskins JT, Moyer JA, Muth EA, Sigg EB, DMI, Wy-45,030, Wy-45,881 and ciramadol inhibit locus coeruleus neuronal activity. Eur J Pharmacol. 1985;115: 139-146.
3. Moyer JA, Muth EA, Haskins JT, Lappe RW, Sigg EB. In vivo antidepressant profiles of the novel bicyclic compounds Wy-45,030 and Wy-45,881 [abstract]. Soc Neurosci Abstracts, 1984;10:261.
4. Nelson JC, Mazure CM, Bowers MB Jr, Jatlow PI. A preliminary, open study of the combination of fluoxetine and desipramine for rapid treatment of major depression. Arch Gen Psychiatry. 1991;48:303-307.
5. Rudolph RL, Fabre LF, Feighner JP, Rickels K, Entsuah R. Derivan AT. A randomized, placebo-controlled, dose-response trial of venlafaxine hydrochloride in the treatment of major depression. J Clin Psychiatry. 1998;59:116-122.
6. Lecrubier Y. Clinical utility of venlafaxine in comparison with other antidepressants. Int J Clin Pharmacol. 1995;10(suppl 2):29-35.
7. Ghose K. Biochemical assessment of antidepressive drugs. Br J Clin Pharmacol. 1980;10:539-550.
8. Tuomisto J, Tukiainen E, Ahlfors UG. Decreased uptake of 5-hydroxytryptamine in blood platelets from patients with endogenous depression. Psychopharmacology. 1979;65:141-147.
9. Montgomery SA, Rasmussen JGC, Lyby K, Connor P, Tanghoj P. Dose response relationship of citalopram 20 mg, citalopram 40 mg and placebo in the treatment of moderate and severe depression. Int J Clin Pharmacol. 1992;6 (suppl 5):65-70.
10. Bjerkenstedt L, Flyckt L, Overo KF, Lingjaerde O. Relationship between clinical effects, serum drug concentration and serotonin uptake inhibition in depressed patients treated with citalopram. Eur J Clin Pharmacol. 1985;28:553-557.
11. Lemberger L, Bergstrom RF, Wolen RL, Farid NA, Enas GG, Aronoff GR. Fluoxetine: clinical pharmacology and physiologic disposition. J Clin Psychiatry. 1985; 46:14-19.
12. Foglia JP, Perel JM, Nathan RS, Pollock BG. Therapeutic drug monitoring (TDM) of fluvoxamine, a selective antidepressant [abstract]. Clin Chem. 1990; 36:1043.
13. Muck-Seler D, Jakovljevic M, Deanovic Z. Effect of antidepressant treatment on platelet 5-HT content and relation to therapeutic outcome in unipolar depressive patients. J Affect Disord. 1991;23:157-164.
14. Marsden CA, Tyrer P, Casey P, Seivewright N. Changes in human whole blood 5-hydroxytryptamine (5-HT) and platelet 5-HT uptake during treatment with paroxetine, a selective 5-HT uptake inhibitor. J Psychopharmacol. 1987;1: 244-250.
15. Preskorn SH, Harvey A. Biochemical and clinical dose-response curves with sertraline [abstract]. Clin Pharmacol Ther. 1996;59:180.
16. Klamerus KJ, Maloney K. Rudolph RL, Sisenwine SF, Jusko WJ, Chiang ST. Introduction of a composite parameter to the pharmacokinetics of venlafaxine and its active o-desmethyl metabolite. J Clin Pharmacol. 1992;32:716-724.
17. Sertraline [package insert]. New York, NY: Pfizer Inc; 1997.
18. Ludiomil [package insert]. Basel. Switzerland: Ciba-Geigy AG: 1997.
19. Muth EA, Moyer JA, Haskins JT, Andree TH, Husbands GEM. Biochemical, neurophysiological, and behavioral effects of Wy-45,233 and other identified metabolites of the antidepressant venlafaxine. Drug Dev Res. 1991;23:191-199.
20. Tuomisto J. A new modification for studying 5-HT uptake by blood platelets: a re-evaluation of tricyclic antidepressants as uptake inhibitors. J Pharm Pharmacol. 1974;26:92-100.
21. Ghose K. Assessment of peripheral adrenergic activity and its interactions with drugs in man. Eur J Clin Pharmacol. 1980;17:233-238.
22. Bolden-Watson C, Richelson E. Blockade by newly-developed antidepressants of biogenic amine uptake into rat brain synaptosomes. Life Sci. 1993;52:1023-1029.
23. Ishigooka J, Kasabara T. Nagata E. Murasaki M, Miura S. Effects of washing procedure on platelets pretreated with serotonin uptake inhibitors in vitro: low K, values predict long-lasting inhibition of serotonin uptake in vivo. Nihon Shinkei Seishin Yakurigaku Zasshi 1998;1:19-21.
24. Ross SB. Aperia B, Beck-Friis J, Jansa S, Wetterberg L, Aberg G. Inhibition of 5-hydroxytryptamine uptake in human platelets by antidepressant agents in vivo. Psychopharmacology. 1980;67:1-7.
25. Malmgren R. Methodological aspects of studies on the 5-HT uptake mechanism in normal platelets. Acta Pharmacol Toxocol. 1981;49:277-284.
26. Charney DS. Monamine dysfunction and the pathophysiology and treatment of depression. J Clin Psychiatry. 1998;59(suppl 14):11-14.
27. Nelson CJ. Augmentation strategies with serotonergic-noradrenergic combinations. J Clin Psychiatry. 1998:59(suppl 5):65-68.